Longeveron Inc. (NasdaqCM: LGVN)
Health Care · Biotechnology · US
$0.84
+14.19% today · +8.4% 1Y
Longeveron Inc. (NasdaqCM: LGVN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $26.94M and employs 38 people.
Over the last twelve months the share price has gained 8.4%, trading between 0.48 and 1.23.
Tweenvest scores Longeveron Inc. across four factors: quality 27/100, value 44/100, growth 0/100. Its strongest factor is value.
LGVN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $26.94M
- Revenue (TTM)
- $1.19M
- P/E
- —
- EPS
- -0.97
- Dividend yield
- —
- Beta (5Y)
- -0.25
- 52-week high
- $1.23
- 52-week low
- $0.48
- Avg volume (3M)
- —
- Shares outstanding
- 31.88M
- Employees
- 38
- Next earnings
- —
About Longeveron Inc.
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
- Founded
- 2014
- Listed since
- Feb 12, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.92 | -1.48% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.